Shots:

• The companies have initiated a rolling submission for EUA of COVID-19 Vaccine in children aged 6mos. to <5yrs. The submission was based on the totality of data on the safety, tolerability, immunogenicity & efficacy of two 3 µg doses of COVID-19 vaccine & the submission is expected to be complete in the coming days
• The companies are planning to share the data with the EMA & other regulatory agencies globally & will submit additional data on a third 3 µg dose in the coming mos., after completion of 2nd dose
• If authorization is granted, it will be the 1st COVID-19 vaccine for pediatric populations under 5yrs. of age. The vaccine is already authorized for use in children aged ≥5yrs.

Ref: Businesswire | Image: Pfizer